Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials.

Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109.

2.

A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.

Gold B, Warrier T, Nathan C.

Methods Mol Biol. 2015;1285:293-315. doi: 10.1007/978-1-4939-2450-9_18.

PMID:
25779324
3.

Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis.

Zheng P, Somersan-Karakaya S, Lu S, Roberts J, Pingle M, Warrier T, Little D, Guo X, Brickner SJ, Nathan CF, Gold B, Liu G.

J Med Chem. 2014 May 8;57(9):3755-72. doi: 10.1021/jm4019228.

PMID:
24694175
4.

TB drug development: immunology at the table.

Nathan C, Barry CE 3rd.

Immunol Rev. 2015 Mar;264(1):308-18. doi: 10.1111/imr.12275. Review.

5.

A high-throughput cidality screen for Mycobacterium tuberculosis.

Kaur P, Ghosh A, Krishnamurthy RV, Bhattacharjee DG, Achar V, Datta S, Narayanan S, Anbarasu A, Ramaiah S.

PLoS One. 2015 Feb 18;10(2):e0117577. doi: 10.1371/journal.pone.0117577.

6.

Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis.

Warrier T, Martinez-Hoyos M, Marin-Amieva M, Colmenarejo G, Porras-De Francisco E, Alvarez-Pedraglio AI, Fraile-Gabaldon MT, Torres-Gomez PA, Lopez-Quezada L, Gold B, Roberts J, Ling Y, Somersan-Karakaya S, Little D, Cammack N, Nathan C, Mendoza-Losana A.

ACS Infect Dis. 2015 Dec 11;1(12):580-5. doi: 10.1021/acsinfecdis.5b00025.

PMID:
27623055
8.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
9.

S-nitroso proteome of Mycobacterium tuberculosis: Enzymes of intermediary metabolism and antioxidant defense.

Rhee KY, Erdjument-Bromage H, Tempst P, Nathan CF.

Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):467-72.

10.

Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.

Darby CM, Ingólfsson HI, Jiang X, Shen C, Sun M, Zhao N, Burns K, Liu G, Ehrt S, Warren JD, Andersen OS, Brickner SJ, Nathan C.

PLoS One. 2013 Jul 30;8(7):e68942. doi: 10.1371/journal.pone.0068942. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/760b5b07-4922-42c4-b33a-162c1e9ae188. Anderson, Olaf S [corrected to Andersen, Olaf S].

11.

Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.

Speer A, Shrestha TB, Bossmann SH, Basaraba RJ, Harber GJ, Michalek SM, Niederweis M, Kutsch O, Wolschendorf F.

Antimicrob Agents Chemother. 2013 Feb;57(2):1089-91. doi: 10.1128/AAC.01781-12.

12.

A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.

Ozeki Y, Igarashi M, Doe M, Tamaru A, Kinoshita N, Ogura Y, Iwamoto T, Sawa R, Umekita M, Enany S, Nishiuchi Y, Osada-Oka M, Hayashi T, Niki M, Tateishi Y, Hatano M, Matsumoto S.

PLoS One. 2015 Nov 16;10(11):e0141658. doi: 10.1371/journal.pone.0141658.

13.

Nitrite impacts the survival of Mycobacterium tuberculosis in response to isoniazid and hydrogen peroxide.

Cunningham-Bussel A, Bange FC, Nathan CF.

Microbiologyopen. 2013 Dec;2(6):901-11. doi: 10.1002/mbo3.126.

14.

High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.

Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, Hafsat S, Sherman DR, Wang MW.

PLoS One. 2012;7(6):e39961. doi: 10.1371/journal.pone.0039961.

15.

Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection.

Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9819-24. doi: 10.1073/pnas.1000715107.

16.

Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis.

Lilienkampf A, Pieroni M, Franzblau SG, Bishai WR, Kozikowski AP.

Curr Top Med Chem. 2012;12(7):729-34. Review.

PMID:
22283815
17.

A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen.

Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, Pawar S, Rogers L, Kolattukudy PE.

PLoS One. 2009 Jun 29;4(6):e6077. doi: 10.1371/journal.pone.0006077.

18.

[A study on the drug resistance to p-nitrobenzoic acid in Mycobacterium tuberculosis].

Wu LZ, Pan MY, Liu X, Zhou HM, Wu XY, Luo CM.

Zhonghua Jie He He Hu Xi Za Zhi. 2011 Feb;34(2):117-9. Chinese.

PMID:
21426730
19.

Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics.

Buchmeier NA, Newton GL, Koledin T, Fahey RC.

Mol Microbiol. 2003 Mar;47(6):1723-32.

20.

Whole cell screen based identification of spiropiperidines with potent antitubercular properties.

Tantry SJ, Degiacomi G, Sharma S, Jena LK, Narayan A, Guptha S, Shanbhag G, Menasinakai S, Mallya M, Awasthy D, Balakrishnan G, Kaur P, Bhattacharjee D, Narayan C, Reddy J, Naveen Kumar CN, Shandil R, Boldrin F, Ventura M, Manganelli R, Hartkoorn RC, Cole ST, Panda M, Markad SD, Ramachandran V, Ghorpade SR, Dinesh N.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3234-45. doi: 10.1016/j.bmcl.2015.05.087.

PMID:
26087937
Items per page

Supplemental Content

Support Center